Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PWIB123on Dec 14, 2022 11:00am
142 Views
Post# 35170842

RE:RE:RE:RE:RE:RE:RE:Great opportunity!

RE:RE:RE:RE:RE:RE:RE:Great opportunity!I prefer Free Cash Flow as a measure, but we still need to understand the impact of interest expense as the company has already put a debt financing deal on the table.  You have to give consideration to working capital and those balance sheet items are not just noise.  You sell inventory, you have to buy more inventory.  You use cash by extending terms with A/R, and you may not have exactly equal terms with your A/P, so there's a use of cash.  But then, A/R get paid and that brings in cash.  Inventory write-off is a use of cash, because that asset is no longer part of your working capital, and then you have to buy more inventory to replace what you had.  The balance sheet is litterred with these kinds of activities that do indeed impact when you receive cash or when cash is needed to be used.  You cannot ignore them, and you have to understand that a company can generate cash or limit the use of cash by doing things like offering discounts for early pay on receivables, delaying the purchases of new inventory while using up what's already on the balance sheet, slow paying payables.  That feels like nosie at times, but it's what CFO's do to take advantage of current market conditions.  So, working capital needs are hard to decipher maybe at times, but growing revenue more often than not results in a use of cash even while profit is increasing, but I don't have a good feel for the company's terms with customers and suppliers.

I actually can't stand the way the CFO presents the financials.  I think it's too basic and if all you did was spread the financials and compare period-over-period or year-over-year and state the differences, you'd get close to his reports.

houbahop wrote: "You have to figure in the change in the balance sheet since it either gives you cash (like lower inventories), or uses your cash. Only way to figure full operational cash flow...."

Quite the opposite. Fluctuations in balance sheet items is noise when you analyse CFFO.


<< Previous
Bullboard Posts
Next >>